EUCTR2008-001736-12-BE进行中（未招募）不适用
A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), onprogression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients, age =18 years
- •2. Able to comply with the protocol
- •3. Patients must be able to take oral medication
- •4. Histologically documented inoperable, locally advanced or metastatic (stage IIIB and stage IV) NSCLC. (NOTE: Sputum cytology alone is not acceptable). Tumors with mixed histology should be categorized according to the predominant cell type
- •5. Prior Treatment: Failed at least one, but no more than two standard chemotherapy regimens
- •6. Patients who have received maintenance chemotherapy between initial course of therapy (first line) and study entry may enter on the study provided they have not been treated with an agent that targets EGFR or IGF-1R
- •7. Formalin fixed paraffin embedded tumor tissue samples from initial or subsequent diagnosis representative of the disease must be available for shipment to Roche prior to randomization
- •8. Measurable disease according to RECIST
- •9. ECOG performance status 0-2
- •10. Life expectancy > 12 weeks
- •11. Adequate hematological function : ANC =1.5 x 10 to the power 9/L;platelets = 100 x 10to the power 9/L, Hb =9 g/dL
- •12. INR =1.5 and PTT =1.5 x ULN unless receiving anticoagulant therapy
- •13. Adequate liver function: Serum bilirubin =1.5 x ULN; transaminases =2.5 x ULN (in case of liver metastases <5 x ULN)
- •14. Adequate renal function: Serum creatinine = 1.5 X ULN
- •15. Serum calcium = 1.1 X ULN
- •16. HbA1c = 7%
- •17. Negative pregnancy test within 7 days of starting study treatment in pre-menopausal women and women < 2 years after the onset of menopause
- •18. Signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients must have had a head CT/MRI to evaluate for CNS metastasis within 28 days prior to enrollment. Patients with active CNS lesions are excluded. Patients with
- •radiographically stable, asymptomatic previously irradiated lesions are eligible provided patients is = 4 weeks beyond completing cranial irradiation and = 3 weeks off corticosteroid therapy
- •2. Prior treatment with an investigational or commercial agent that acts via IGF-1R inhibition
- •3. Prior treatment with an agent that acts via EGFR targeting
- •4. Administration of any anti-cancer therapies other than those administered in this study during protocol treatment
- •5. Administration of high doses of systemic corticosteroids. High dose is considered more than 1 mg/kg per day of prednisone (or equivalent) for more than 7 consecutive
- •days. Dexamethasone may induce CYP3A4 activity. CYP3A4 inhibitors and inducers may influence the plasma level of erlotinib
- •6. Prior irradiation: 1) Radiotherapy given within the last 4 weeks prior to first dose of study treatment. 2) Palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to the first dose of study treatment
- •7. Prior Surgery: Major Surgery (including open biopsy) or significant traumatic injury within the last 2 weeks prior to first dose of study treatment or anticipation of the need for major surgery during study treatment.
- •Patients who undergo minor surgical procedures (for example, placement of a central venous access device) must be sufficiently recovered from the procedure to receive chemotherapy but do not require a mandatory 14 day interval between the procedure and initiation of study treatment.
- •8. Patients who have not recovered from adverse events to = grade 1, (excluding alopecia) from previously administered therapies and must be randomly assigned to study treatment at least 21 days after chemotherapy (14 days after treatment with vinca alkaloids or gemcitabine)
- •9. Lactating women
- •10. Fertile men and women of childbearing potential not using effective methods to prevent pregnancy throughout the trial and for 90 days after last study drug administration in both sexes. Women of childbearing potential must have a negative pregnancy test (serum ß- HCG) within the 7 days prior to study drug administration.
- •- NOTE: Women of childbearing potential includes both pre-menopausal women and women within the first 2 years of the onset of menopause
- •- NOTE: Effective methods of birth control includes: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, abstinence. Oral contraceptive pills (OCPs) alone are not considered an effective method
- •11. Other active cancer requiring treatment
- •12. Known hypersensitivity to any of the study drugs or their excipients
- •13. Any disease (including psychotic disorders, drug abuse, active infection, uncontrolled hypertension, clinically significant cardiovascular disease for example CVA (= 6 months before randomization), myocardial infarction (= 6 months before randomization), unstable angina, NYHA = grade 2 CHF, arrhythmia requiring medication, hepatic, renal or metabolic disease (including uncontrolled diabetes mellitus), metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment related complications
- •14. History of allogeneic bone marrow transplantation or organ
研究者
相似试验
进行中（未招募）
不适用
A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), onprogression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy.To investigate in a randomized fashion if the addition of targeted IGF-1R blockade with R1507 has additional clinical benefit when combined with erlotinib in patients with advanced NSCLC who have failed at least one, but no more than two standard chemotherapy regimens. The study will also investigate 2 doses and schedules of R1507 combined with erlotinib compared with erlotinib and placebo, and assess the safety and tolerability of the combination in this patient population.MedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-001736-12-DEF. Hoffmann-La Roche Ltd150
进行中（未招募）
1 期
A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapyEUCTR2008-001736-12-GBF. Hoffmann-La Roche Ltd150
已完成
不适用
A randomized placebo-controlled trial to determine the effect of iron supplementation on hematological indices in pregnant women with hemoglobin =13.2 g/dlPregnant women of high hemoglobin.Abnormal haematological finding on antenatal screening of motherIRCT138710181531N1Tarbiat Modarres University87
已完成
3 期
MObILE study - Midodrine effect on Orthostatic IntoLErance after hip and knee replacementsOrthostatic HypotensionACTRN12620001342909Waitemata District Health Board170
已完成
不适用
A randomised controlled trial investigating the effectiveness of pulsed electrical stimulation in treating osteoarthritis of the kneeOstearthritis of the kneeMusculoskeletal - OsteoarthritisACTRN12607000492459Robyn Fary70